| Title |
What do we know about IDH1/2 mutations so far, and how do we use it?
|
|---|---|
| Published in |
Acta Neuropathologica, March 2013
|
| DOI | 10.1007/s00401-013-1106-9 |
| Pubmed ID | |
| Authors |
Craig Horbinski |
| Abstract |
Whole genome analyses have facilitated the discovery of clinically relevant genetic alterations in a variety of diseases, most notably cancer. A prominent example of this was the discovery of mutations in isocitrate dehydrogenases 1 and 2 (IDH1/2) in a sizeable proportion of gliomas and some other neoplasms. Herein the normal functions of these enzymes, how the mutations alter their catalytic properties, the effects of their D-2-hydroxyglutarate metabolite, technical considerations in diagnostic neuropathology, implications about prognosis and therapeutic considerations, and practical applications and controversies regarding IDH1/2 mutation testing are discussed. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 60% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 60% |
| Scientists | 2 | 40% |
Mendeley readers
The data shown below were compiled from readership statistics for 124 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | <1% |
| Sweden | 1 | <1% |
| United Kingdom | 1 | <1% |
| Belgium | 1 | <1% |
| Nigeria | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 118 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 25 | 20% |
| Researcher | 23 | 19% |
| Student > Bachelor | 17 | 14% |
| Student > Master | 16 | 13% |
| Student > Doctoral Student | 7 | 6% |
| Other | 17 | 14% |
| Unknown | 19 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 41 | 33% |
| Biochemistry, Genetics and Molecular Biology | 25 | 20% |
| Agricultural and Biological Sciences | 18 | 15% |
| Neuroscience | 5 | 4% |
| Chemistry | 4 | 3% |
| Other | 10 | 8% |
| Unknown | 21 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 December 2018.
All research outputs
#8,381,663
of 25,042,800 outputs
Outputs from Acta Neuropathologica
#1,490
of 2,513 outputs
Outputs of similar age
#68,750
of 202,567 outputs
Outputs of similar age from Acta Neuropathologica
#8
of 24 outputs
Altmetric has tracked 25,042,800 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,513 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.4. This one is in the 15th percentile – i.e., 15% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 202,567 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.